reviewAnnual Review of MedicineFeb 1, 2002Closed access

Cyclooxygenase-2: A Therapeutic Target

Nestlé (Switzerland) · Vanderbilt University Medical Center

PubMed
Indexed incrossrefpubmed

Abstract

Cyclooxygenase (COX), also known as prostaglandin endoperoxide synthase, is the key enzyme required for the conversion of arachidonic acid to prostaglandins. Two COX isoforms have been identified, COX-1 and COX-2. In many situations, the COX-1 enzyme is produced constitutively (e.g., in gastric mucosa), whereas COX-2 is highly inducible (e.g., at sites of inflammation and cancer). Traditional nonsteroidal anti-inflammatory drugs (NSAIDs) inhibit both enzymes, and a new class of COX-2 selective inhibitors (COXIBs) preferentially inhibit the COX-2 enzyme. This review summarizes our current understanding of the role of COX-1 and COX-2 in normal physiology and disease.

Citation impact

680
total citations
FWCI
30.73
Percentile
100%
References
166
Citations per year

Authors

2

Topics & keywords

Keywords
  • Cyclooxygenase
  • Enzyme
  • Arachidonic acid
  • Gene isoform
  • Prostaglandin
  • Inflammation
  • Pharmacology
  • Prostaglandin H2
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.